Navigation Links
BioLife Solutions Appoints Raymond W. Cohen as Chairman and Joe Schick to Board of Directors
Date:11/19/2013

BOTHELL, Wash., Nov. 19, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has appointed a new chairman of the board and also a new director.

Current board director Raymond Cohen was appointed non-executive Chairman of the Board, replacing Mike Rice, President & CEO, who remains in that role and on the board.  Cohen is currently the Chairman of the Board of Lombard Medical Technologies, PLC, a UK public medical device company.  He is also Chairman of the Board of JenaValve Technology, Inc., a privately held, Munich-based medical device company.  Cohen is also a director of Spectrum Pharmaceuticals, Syncroness, Inc., and LoneStar Heart, Inc. He was most recently the Chief Executive Officer of Vessix Vascular, Inc., and led its November 2012 acquisition by Boston Scientific, a deal valued at up to $425 million.

The Company also announced that Joe Schick, a senior financial leader for several high growth companies, has joined its board of directors, replacing Roderick de Greef, who resigned from the board to devote time to his personal interests.  Schick is currently the Chief Financial Officer of Corbis Corporation, a privately held global digital media company. Concurrent with
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioLife Solutions Completes First $1 Million Revenue Quarter
2. BioLife Solutions Appoints Rick Stewart To Board of Directors
3. BioLife Solutions Announces 2012 Full Year Results; 10th Consecutive Quarter of Record Revenue
4. BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
5. BioLife Solutions Announces the Addition of Robert Preti, Ph.D. to its Scientific Advisory Board
6. BioLife Solutions and SAVSU Technologies Announce Exclusive Distribution Agreement
7. BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
8. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
9. Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions
10. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
11. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium ... today positive preliminary results from its Phase II ... prednisone (D/P) in men with docetaxel refractory, castrate ... of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in ...
... Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation ... the status of its new drug application ("NDA") for AFRESA(R), ... trials. As previously announced, our internal goal was to ... by the end of February. Based on editorial decisions ...
Cached Medicine Technology:Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 2Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 3Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 4MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... Reporter , MONDAY, Sept. 13 (HealthDay News) -- The U.S. ... this week whether or not the diet drug Meridia should ... released Monday ahead of the panel meeting, which begins Wednesday, ... Drugs Advisory Committee will be asked to consider a number ...
... of the National Institutes of Health, announced today that ... Institutes in San Francisco, Calif., has been selected as ... HIV/AIDS Research for his proposal to study the mechanisms ... now in its third year, is intended to stimulate ...
... study describing a newly developed pharmacological inhibitor is providing ... implicated in multiple human malignancies regulates a known tumor ... September 14th issue of the journal Cancer Cell ... Mitogen-activated protein kinases (MAPKs) are enzymes that regulate ...
... that spurs the progression of non-small-cell lung cancer could become ... Southwestern Medical Center, who published a study on how the ... Cancer Cell . Scientists have known that the ... human tumors, including non-small-cell lung cancer (NSCLC). Until now, however, ...
... Earthy or musty odors, along with visual evidence of ... a warning that harmful cyanotoxins are present in lakes ... cyanobacterial blooms in Midwest lakes, taste-and-odor compounds were found ... serve as a warning that harmful toxins are present. ...
... findings from a major drug trial have brought experts a ... of British deaths from heart attacks. Dr Robert ... at Sheffield Teaching Hospitals, was the UK lead for international ... place over the last six years. The new findings ...
Cached Medicine News:Health News:FDA Panel to Mull Ban on Diet Drug Meridia 2Health News:FDA Panel to Mull Ban on Diet Drug Meridia 3Health News:Latent HIV infection focus of NIDA's 2010 Avant-Garde Award 2Health News:Selective inhibition of BMK1 suppresses tumor growth 2Health News:Lung cancer culprit could offer target for therapy, UT Southwestern researchers report 2Health News:If the water looks and smells bad, it may be toxic 2Health News:Breakthrough in drug trial offers hope for heart attack patients 2
... facilities, recreational venues and more ... provide automated data capture that ... reducing costly and dangerous errors. ... print quality and color-coding options ...
... Laser Sheeted Wristband / ... laser-printable sheets with an ... laser labels that adhere ... clear, fold-over protective window ...
As part of a complete all-in-one system, Sentry LabelBand securely seals inexpensive paper labels inside a clear, adhesive shield. LabelBand provides easy and accurate bar code scanning and protectio...
... Thermal Printing Wristbands and Tags print ... and thermal transfer printers. Direct thermal ... heat-sensitive thermal coating under the bands ... heat to transfer highly durable ink ...
Medicine Products: